Skip to content
RestemRestem
  • Menu
  • Our Science
    • Our Cells
    • ULSCs
    • NK Cells
    • Compassionate Use Policy
  • Our Trials
    • COVID
    • Muscular Dystrophy
    • Autoimmune
    • Heart Failure
  • Our Company
    • Team
    • Advisors
    • Partners
    • Careers
  • Investors & Media
    • Corporate Profile
    • Publications
    • Press Releases
  • Contact
Announcements

Restem

Posted on January 6, 2019July 1, 2020 by michelleibarra

RESTEM acquires umbilical cord lining stem cells (ULSCs) technology rights in full to include all intellectual property of such, previous studies and any/all research & development previously completed on ULSCs.

University of Murcia
Latest Posts
  • 14
    May
    FDA approves COVID-19 treatment after successful use of STEM CELLS from RESTEM Comments Off on FDA approves COVID-19 treatment after successful use of STEM CELLS from RESTEM
  • 08
    May
    Florida Mom Recovers From Covid-19 with Stem Cell Therapy Comments Off on Florida Mom Recovers From Covid-19 with Stem Cell Therapy
  • 08
    May
    Patient Credits Stem Cell Treatment With Saving Her Life Comments Off on Patient Credits Stem Cell Treatment With Saving Her Life
  • 07
    May
    COVID-19: Three Patients Successfully Treated with RESTEM Stem Cells Comments Off on COVID-19: Three Patients Successfully Treated with RESTEM Stem Cells
  • 07
    May
    3 Miami COVID-19 Patients Successfully Recovered with Stem Cell Therapy Comments Off on 3 Miami COVID-19 Patients Successfully Recovered with Stem Cell Therapy
Categories
  • Announcements (4)
  • News (5)
Copyright 2023 © Restem
  • Our Science
    • Our Cells
    • ULSCs
    • NK Cells
    • Compassionate Use Policy
  • Our Trials
    • COVID
    • Muscular Dystrophy
    • Autoimmune
    • Heart Failure
  • Our Company
    • Team
    • Advisors
    • Partners
    • Careers
  • Investors & Media
    • Corporate Profile
    • Publications
    • Press Releases
  • Contact